MX352478B - Proteina vp6 de la capside de norovirus y rotavirus para el uso como vacuna combinada. - Google Patents

Proteina vp6 de la capside de norovirus y rotavirus para el uso como vacuna combinada.

Info

Publication number
MX352478B
MX352478B MX2013004159A MX2013004159A MX352478B MX 352478 B MX352478 B MX 352478B MX 2013004159 A MX2013004159 A MX 2013004159A MX 2013004159 A MX2013004159 A MX 2013004159A MX 352478 B MX352478 B MX 352478B
Authority
MX
Mexico
Prior art keywords
rotavirus
norovirus
protein
combined vaccine
vlps
Prior art date
Application number
MX2013004159A
Other languages
English (en)
Other versions
MX2013004159A (es
Inventor
Timo Vesikari
Blazevic Vesna
Nurminen Kirsi
Huhti Leena
Lappalainen Suvi
Jokela Eeva
Original Assignee
Blazevic Vesna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Blazevic Vesna filed Critical Blazevic Vesna
Publication of MX2013004159A publication Critical patent/MX2013004159A/es
Publication of MX352478B publication Critical patent/MX352478B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12323—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a una vacuna combinada de norovirus y de rotavirus para la prevención de la infección causada por norovirus y rotavirus y/o de la enfermedad con diarrea y vómito inducida por el virus en los humanos. Más específicamente, la invención comprende un método para preparar las composiciones de vacuna combinada que comprenden los antígenos de norovirus y de rotavirus, particularmente las mezclas de las VLP de norovirus y de proteína recombinante VP6 del rotavirus o de las VLP bicapa de VP2/VP6. Además, la invención se relaciona con los métodos para inducir una inmunorespuesta.
MX2013004159A 2010-10-14 2011-10-12 Proteina vp6 de la capside de norovirus y rotavirus para el uso como vacuna combinada. MX352478B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39308110P 2010-10-14 2010-10-14
FI20106067A FI122520B (fi) 2010-10-15 2010-10-15 Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
PCT/FI2011/050880 WO2012049366A1 (en) 2010-10-14 2011-10-12 Norovirus capsid and rotavirus vp6 protein for use as combined vaccine

Publications (2)

Publication Number Publication Date
MX2013004159A MX2013004159A (es) 2013-11-04
MX352478B true MX352478B (es) 2017-11-27

Family

ID=43064225

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013004159A MX352478B (es) 2010-10-14 2011-10-12 Proteina vp6 de la capside de norovirus y rotavirus para el uso como vacuna combinada.

Country Status (14)

Country Link
US (1) US8895015B2 (es)
EP (1) EP2627353B1 (es)
JP (1) JP5902181B2 (es)
KR (1) KR101847472B1 (es)
CN (1) CN103260645B (es)
AU (1) AU2011315405B2 (es)
BR (1) BR112013009164A2 (es)
CA (1) CA2814175C (es)
FI (1) FI122520B (es)
MX (1) MX352478B (es)
RU (1) RU2013121815A (es)
SG (1) SG189398A1 (es)
TW (1) TWI479022B (es)
WO (1) WO2012049366A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5284290B2 (ja) 2007-03-14 2013-09-11 リゴサイト ファーマスーティカルズ，インコーポレイテッド ウイルス様粒子の精製
WO2013061941A1 (ja) 2011-10-24 2013-05-02 トヨタ自動車株式会社 組換え酵母を用いたエタノールの製造方法
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
CN103667199B (zh) 2012-09-20 2019-01-22 厦门大学 体外制备轮状病毒双层类病毒颗粒的方法
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
AU2014236340B2 (en) * 2013-03-14 2019-01-17 Massachusetts Institute Of Technology Nanoparticle-based compositions
JP2015015931A (ja) * 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
JP2018078806A (ja) * 2016-11-14 2018-05-24 東ソー株式会社 ノロウイルスｒｎａの検出方法
US11833198B2 (en) 2017-03-28 2023-12-05 Children's Hospital Medical Center Norovirus S particle based vaccines and methods of making and using same
EP3625246A1 (en) 2017-05-18 2020-03-25 ModernaTX, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
JP6879111B2 (ja) 2017-08-02 2021-06-02 トヨタ自動車株式会社 組換え酵母及びこれを用いたエタノールの製造方法
KR102038364B1 (ko) 2018-03-15 2019-10-30 전남대학교 산학협력단 소 로타바이러스 감염증 예방용 약독화 혼합생백신 조성물
BR112022013537A2 (pt) 2020-01-08 2022-11-22 Bharat Biotech Int Ltd Composições de vacina viral e métodos de preparações das mesmas
CN111265660B (zh) * 2020-01-19 2022-11-15 青岛明勤生物科技有限公司 一种通用型疫苗免疫增强剂
CN114316009B (zh) * 2020-09-29 2023-04-25 上海交通大学 一种能够结合多种病毒的蛋白及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298244A (en) * 1990-10-25 1994-03-29 University Of Saskatchewan Assembled viral particles and their use in a vaccine to rotaviral disease
IE920366A1 (en) 1991-02-04 1992-08-12 Univ Saskatchewan Vp6 encapsulated drug delivery
US6673355B1 (en) 1995-06-14 2004-01-06 Baylor College Of Medicine Rotavirus enterotoxin NSP4 and methods of using same
JP2000139473A (ja) * 1998-11-16 2000-05-23 Hokkaido Green Bio Kenkyusho:Kk ロタウイルス遺伝子を導入した遺伝子組換え植物、この遺伝子組換え植物に由来するロタウイルスのタンパク質及びこのロタウイルスのタンパク質に対する抗体
US20030166139A1 (en) 2001-07-20 2003-09-04 Choi Anthony H. Rotavirus VP6 subunit
WO2006138514A2 (en) * 2005-06-16 2006-12-28 Children's Hospital Medical Center Novel norovirus particle for use as an antiviral or vaccine
US8168202B2 (en) 2005-07-07 2012-05-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Hexavalent bovine rotavirus reassortant composition designed for use in developing countries
WO2007081447A2 (en) * 2005-11-22 2007-07-19 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
AU2008302276B2 (en) * 2006-09-29 2013-10-10 Takeda Vaccines, Inc. Method of conferring a protective immune response to norovirus
JP5284290B2 (ja) * 2007-03-14 2013-09-11 リゴサイト ファーマスーティカルズ，インコーポレイテッド ウイルス様粒子の精製
WO2009127519A1 (en) * 2008-04-18 2009-10-22 Unilever Nv Compositions comprising antibodies or antibody fragments
WO2010006326A2 (en) * 2008-07-11 2010-01-14 Tufts University Methods and compositions for spore-based vaccines
CN102612525A (zh) * 2009-06-09 2012-07-25 儿童医院医疗中心 抗原-诺罗病毒p-结构域单体和二聚体，抗原-诺罗病毒p-粒子分子，及其制备和应用方法

Also Published As

Publication number Publication date
SG189398A1 (en) 2013-05-31
BR112013009164A2 (pt) 2019-09-24
JP5902181B2 (ja) 2016-04-13
FI122520B (fi) 2012-03-15
CN103260645A (zh) 2013-08-21
EP2627353A4 (en) 2014-06-18
KR20140030100A (ko) 2014-03-11
US8895015B2 (en) 2014-11-25
EP2627353A1 (en) 2013-08-21
FI20106067A0 (fi) 2010-10-15
AU2011315405B2 (en) 2016-09-22
TWI479022B (zh) 2015-04-01
CN103260645B (zh) 2016-03-16
AU2011315405A1 (en) 2013-05-23
EP2627353B1 (en) 2017-11-29
MX2013004159A (es) 2013-11-04
CA2814175C (en) 2019-11-05
WO2012049366A1 (en) 2012-04-19
CA2814175A1 (en) 2012-04-19
US20120093884A1 (en) 2012-04-19
TW201217530A (en) 2012-05-01
KR101847472B1 (ko) 2018-04-11
RU2013121815A (ru) 2014-11-20
JP2013540773A (ja) 2013-11-07

Similar Documents

Publication Publication Date Title
MX352478B (es) Proteina vp6 de la capside de norovirus y rotavirus para el uso como vacuna combinada.
MX352324B (es) Vacunas multivalentes de nanovehiculos sinteticos.
PH12018501602A1 (en) Subunit immersion vaccines for fish
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
PH12017500727A1 (en) Modified virus-like particles of cmv
WO2012027365A3 (en) Targeted multi-epitope dosage forms for induction of an immune response to antigens
WO2011112945A3 (en) Foot and mouth disease virus recombinant vaccines and uses thereof
WO2013054199A3 (en) Cmv antigens and uses thereof
IL215430A (en) Immunogenic and antiviral vaccines and their use
EP3266464A3 (en) Yeast-based therapeutic for chronic hepatitis b infection
MX344103B (es) Vacunas de virus herpes vectorizado con virus de enfermedad de newcastle.
WO2007147529A3 (en) Recombinant viral vaccine
EP2525816A4 (en) PRESENTATION OF TARGETED HETEROLOGOUS ANTIGENS ON CALICIVIRUS VIRAL PSEUDO PARTICLES
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
WO2011094363A3 (en) Influenza virus compositions and methods for universal vaccines
PL2658570T3 (pl) Sposoby i kompozycje szczepionki przeciwko wirusowi wirusowej biegunki bydła typu 1b
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
MY189495A (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
WO2012174455A3 (en) Group a streptococcus multivalent vaccine
WO2014140166A3 (en) Vaccine
WO2011074006A3 (en) Vaccine composition
WO2014008475A3 (en) Compositions and methods related to viral vaccines
MX350718B (es) Vacuna de rinitis equina.
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа
WO2014167582A3 (en) Vaccine composition for prophylaxis in ruminants

Legal Events

Date Code Title Description
FG Grant or registration